Presseportal.de - Ototoxicityhttps://www.presseportal.de/en/st/OtotoxicityPresseportal - the leading German database for press releases - a service of news aktuell, a company of the dpa Group en-ennews aktuell GmbHhttps://www.presseportal.de/images/logos/logo-de-250.jpgPresseportal.de - Ototoxicityhttps://www.presseportal.de/en/st/Ototoxicityinfo@presseportal.de (presseportal.de)Sat, 13 Jun 2026 05:50:07 +0200Fri, 12 Jun 2026 09:00:00 +0200Ototoxicity6Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced OtotoxicityAcousia Therapeutics GmbH: Tübingen (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study. ...https://www.presseportal.de/en/pm/161203/6292947Fri, 12 Jun 2026 09:00:00 +0200https://www.presseportal.de/en/pm/161203/6292947 Acousia Therapeutics GmbH [Newsroom]
Tübingen (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study. ... Lesen Sie hier weiter...

Original content of: Acousia Therapeutics GmbH, transmitted by news aktuell

]]>Health / Medicineinfo@presseportal.de (presseportal.de)Acousia Therapeutics GmbHAcousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced OtotoxicityAcousia Therapeutics GmbH: Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ...https://www.presseportal.de/en/pm/161203/6192123Thu, 08 Jan 2026 09:00:00 +0100https://www.presseportal.de/en/pm/161203/6192123 Acousia Therapeutics GmbH [Newsroom]
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ... Lesen Sie hier weiter...

Original content of: Acousia Therapeutics GmbH, transmitted by news aktuell

]]>Health / Medicineinfo@presseportal.de (presseportal.de)Acousia Therapeutics GmbHAcousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR StudyAcousia Therapeutics GmbH: Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced ...https://www.presseportal.de/en/pm/161203/6022071Tue, 29 Apr 2025 09:00:14 +0200https://www.presseportal.de/en/pm/161203/6022071 Acousia Therapeutics GmbH [Newsroom]
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced ... Lesen Sie hier weiter...

Original content of: Acousia Therapeutics GmbH, transmitted by news aktuell

]]>Health / Medicineinfo@presseportal.de (presseportal.de)Acousia Therapeutics GmbHAcousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferencesAcousia Therapeutics GmbH: Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade ...https://www.presseportal.de/en/pm/161203/5841371Mon, 12 Aug 2024 09:00:20 +0200https://www.presseportal.de/en/pm/161203/5841371 Acousia Therapeutics GmbH [Newsroom]
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade ... Lesen Sie hier weiter...

Original content of: Acousia Therapeutics GmbH, transmitted by news aktuell

]]>Health / Medicineinfo@presseportal.de (presseportal.de)Acousia Therapeutics GmbH